These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 34158625)
21. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade. Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800 [TBL] [Abstract][Full Text] [Related]
22. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8 Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114 [TBL] [Abstract][Full Text] [Related]
23. CXCR6 is required for antitumor efficacy of intratumoral CD8 Wang B; Wang Y; Sun X; Deng G; Huang W; Wu X; Gu Y; Tian Z; Fan Z; Xu Q; Chen H; Sun Y J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462326 [TBL] [Abstract][Full Text] [Related]
24. A Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128 [TBL] [Abstract][Full Text] [Related]
25. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy. Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924 [TBL] [Abstract][Full Text] [Related]
26. Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy. Navarro F; Casares N; Martín-Otal C; Lasarte-Cía A; Gorraiz M; Sarrión P; Llopiz D; Reparaz D; Varo N; Rodriguez-Madoz JR; Prosper F; Hervás-Stubbs S; Lozano T; Lasarte JJ Oncoimmunology; 2022; 11(1):2070337. PubMed ID: 35529677 [TBL] [Abstract][Full Text] [Related]
28. Adoptive CD8 Liu S; Liu H; Song X; Jiang A; Deng Y; Yang C; Sun D; Jiang K; Yang F; Zheng Y Nanoscale; 2021 Oct; 13(37):15789-15803. PubMed ID: 34528979 [TBL] [Abstract][Full Text] [Related]
30. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity. Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719 [TBL] [Abstract][Full Text] [Related]
31. The Emerging Role of CD8 Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F Front Immunol; 2018; 9():1904. PubMed ID: 30158938 [TBL] [Abstract][Full Text] [Related]
32. CCL5-deficiency enhances intratumoral infiltration of CD8 Zhang S; Zhong M; Wang C; Xu Y; Gao WQ; Zhang Y Cell Death Dis; 2018 Jul; 9(7):766. PubMed ID: 29991744 [TBL] [Abstract][Full Text] [Related]
33. Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer. Celus W; Oliveira AI; Rivis S; Van Acker HH; Landeloos E; Serneels J; Cafarello ST; Van Herck Y; Mastrantonio R; Köhler A; Garg AD; Flamand V; Tamagnone L; Marine JC; Di Matteo M; Costa BM; Bechter O; Mazzone M Cancer Immunol Res; 2022 Jan; 10(1):126-141. PubMed ID: 34815265 [TBL] [Abstract][Full Text] [Related]
34. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models. Torphy RJ; Sun Y; Lin R; Caffrey-Carr A; Fujiwara Y; Ho F; Miller EN; McCarter MD; Lyons TR; Schulick RD; Kedl RM; Zhu Y Nat Commun; 2022 Jan; 13(1):97. PubMed ID: 35013216 [TBL] [Abstract][Full Text] [Related]
35. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cekic C; Linden J Cancer Res; 2014 Dec; 74(24):7239-49. PubMed ID: 25341542 [TBL] [Abstract][Full Text] [Related]
36. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862 [TBL] [Abstract][Full Text] [Related]
39. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo. Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377 [TBL] [Abstract][Full Text] [Related]
40. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]